IL28B polymorphisms predict interferon-related HBsAg serocl
Date: 2012-04-10 04:02 +300
Subject: IL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAg-negative patients
Hepatology. 2012 Apr 2. doi: 10.1002/hep.25749.
IL28B polymorphisms predict interferon-related HBsAg seroclearance in
genotype D HBeAg-negative patients with chronic hepatitis B.
Lampertico P, Viganò M, Cheroni C, Facchetti F, Invernizzi F, Valveri V,
Soffredini R, Abrignani S, De Francesco R, Colombo M.
Source 1st Division of Gastroenterology, Fondazione IRCCS C? Granda
Ospedale Maggiore Policlinico, Universit? degli Studi di Milano, Milano,
BACKGROUND.: Interleukin(IL)28B polymorphisms have been associated to
interferon(IFN)-induced viral clearance in patients with chronic
hepatitis C. Whether this is also true for patients with the difficult
to cure HBeAg-negative chronic hepatitis B, is unknown. METHODS.: 101
HBeAg-negative patients (92% genotype D) with compensated chronic
hepatitis B (84% males, 46 years, HBV DNA 6.0 log cp/ml, ALT 136 IU/L,
42% with cirrhosis) were followed for a median of 11 (1-17) years after
median 23 (10-48) months of either standard or pegylated (Peg)IFN alfa
therapy. A post-treatment response was defined as HBsAg clearance with
or without anti HBs seroconversion. The rs12979860 (C>T) genotype in the
IL28B locus was assessed in serum samples by using Custom TaqMan SNP
Genotyping Assays. RESULTS.: During a median of 11 years of
post-treatment follow-up, 21 (21%) patients cleared serum HBsAg,
including 15 who developed >10 IU/ml anti-HBs titers. Forty-eight
patients (47%) had CC genotype, 42 (42%) CT and 11 (11%) TT, the allelic
frequency being 68% for C allele and 32% for T allele.
The rate of serum HBsAg clearance was 29% (n=14) in CC compared to 13%
(n=7) in non-CC genotype carriers (p=0.039). Baseline HBV DNA levels 136 IU/ml (OR
6.5, CI 1.8-22.5, p=0.003), duration of IFN (OR 1.16, CI 1.02-1.31,
p=0.021) and genotype CC (OR 3.9, CI 1.1-13.2, p=0.025) independently
predicted HBsAg clearance. CONCLUSIONS.: IL28B polymorphism is an
additional predictor of off-therapy IFN-related HBsAg seroclearance to
be used in pretreatment stratification of HBeAg-negative patients
chronically infected by genotype D of hepatitis B virus. (HEPATOLOGY 2012.).
Copyright 1994-2016 MedHelp International. All rights reserved.
MedHelp is a division of Aptus Health.
This site complies with the HONcode standard for trustworthy health information.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.